DEVICE CATEGORY · NZK
Stimulator, Low Electric Field, Tumor Treatment
Intended to treat tumors by application of low electic fields and indicated for treatment of recurrent glioblastoma multiforme (gbm) in patients who have received maximum standard therapy with continued disease progress, as defined by tumor growth or decline in neurological status.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Novocure GmbHs Optune GioP100034/S045 | Novocure, GmbH | PMA supplement | Sep 18, 2026 | FDA |
Optune HFE Transducer ArraysP100034/S046 | Novocure, GmbH | PMA supplement | Sep 16, 2026 | FDA |
Optune GioP100034/S042 | Novocure, GmbH | PMA supplement | Jun 4, 2026 | FDA |
Optune HFE Transducer Array Soft Part ComponentsP100034/S044 | Novocure, GmbH | PMA supplement | Apr 9, 2026 | FDA |
Optune GioP100034/S043 | Novocure, GmbH | PMA supplement | Feb 25, 2026 | FDA |
Optune Gio - Maxpoint Version 2.0P100034/S041 | Novocure, GmbH | PMA supplement | Oct 23, 2025 | FDA |
| Novocure, GmbH | PMA approval | Apr 8, 2011 | FDA |
Source information
Follow the FDA links to view the original records.






